Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues.
Darouiche
R O
RO
Department of Medicine, Veterans Affairs Medical Center, Houston, Texas 77030, USA.
D000935:Antifungal Agents / Q000627:therapeutic use*; D002180:Candidiasis, Oral / Q000188:drug therapy* / Q000276:immunology; D004352:Drug Resistance, Microbial; D004935:Esophageal Diseases / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology*; D017964:Itraconazole / Q000627:therapeutic use; D009960:Oropharynx; D010608:Pharyngeal Diseases / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology
D000935:Antifungal Agents; D017964:Itraconazole; D015725:Fluconazole